News

Company   Immupharma PLC
TIDM         IMM
Headline    Research Grants
Released    07:00 11-Apr-06
Number     3183B

RNS Number:3183B
Immupharma PLC
11 April 2006

FOR IMMEDIATE RELEASE

London, 11 April 2006

ImmuPharma commences drawdown of prestigious research grants exceeding €1m

ImmuPharma PLC (LSE:IMM), the specialist pharmaceutical discovery and development company, announced today that it has started drawing down independent grants to assist with the development of its lead drug candidates. The grants which were approved in principle at the time of ImmuPharma's AIM admission in February 2006,have been awarded by ANVAR and ANR, two French state organisations that support innovative and promising R&D programmes. These grants were specifically dedicated to the preclinical and clinical development of ImmuPharma's lead compound Lupus IPP-201101 currently in Phase I and to the new class of MRSA antibiotics IPP-203101 presently finishing preclinical development.

Dr Robert Zimmer, President and Chief Scientific Officer, commented: "We are delighted to have been chosen for these grants, out of many companies that have applied. These grants are awarded to promising and solid research oriented companies that can demonstrate strong and innovative research efforts and their ability to conduct developments up to a stage where the products are commercially viable. In addition to strengthening our cash position, receiving these grants from ANVAR and ANR provides further independent validation by prestigious state organisations of ImmuPharma's strength in developing exciting new drugs."

For further information please contact:

ImmuPharma PLC:

Richard Warr, Executive Chairman: tel: +44 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer: tel: +44 20 7152 4080
Dr Robert Zimmer, President & Chief Scientific Officer: tel: + 33 389 32 76 50

or

Buchanan Communications:

Lisa Baderoon, Director: tel: + 44 20 7466 5000

This information is provided by RNS The company news service from the London Stock Exchange

END